Avience Biomedicals
AVIENCE NSE
Avience Biomedicals
HealthcareNSE: AVIENCE Healthcare Equipment & Supplies
Key Fundamentals
SMEMarket Cap
₹183 Cr
Volatility
High Risk
P/E Ratio
21.7
EBITDA
₹10.34 Cr
Return on Equity
31.33%
Debt to Equity
0.92
Book Value
₹164.88
52W High
₹414.95
52W Low
₹208
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 37.9%
Weaknesses
1- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
-8.85% lower than
3Y
Net Income Growth
-19.3% lower than
3Y
Cash Flow Change
232% higher than
3Y
ROE
-9.63% lower than
3Y
ROCE
19.47% level than
3Y
EBITDA Margin (Avg.)
-6.81% lower than
3Y
Quarterly Results
| Particulars | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 24.47 | 26.82 | 25.69 |
| Expenses | 17.86 | 19.57 | 18 |
| Operating Profit | 6.61 | 7.25 | 7.69 |
| OPM % | 27.01% | 27.03% | 29.93% |
| Other Income | 0.46 | 0.06 | 0.23 |
| Interest | 0.69 | 0.65 | 0.89 |
| Depreciation | 0.48 | 0.56 | 0.66 |
| PBT | 5.9 | 6.1 | 6.37 |
| Tax % | 27.63% | 25.74% | 33.75% |
| Net Profit | 4.27 | 4.54 | 4.22 |
| EPS in Rs | 10.59 | 11.26 | 10.47 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 23.83 | 44.92 | 52.51 |
| Expenses | 19.65 | 33.4 | 37.57 |
| Operating Profit | 4.18 | 11.52 | 14.94 |
| OPM % | 17.54% | 25.65% | 28.45% |
| Other Income | 0.41 | 0.58 | 0.29 |
| Interest | 0.94 | 1.45 | 1.54 |
| Depreciation | 0.62 | 0.88 | 1.22 |
| PBT | 3.03 | 9.77 | 12.47 |
| Tax % | 28.71% | 27.33% | 29.75% |
| Net Profit | 2.16 | 7.1 | 8.75 |
| EPS in Rs | 6.58 | 17.61 | 21.71 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 3.28 | 4.03 | 4.03 |
| Reserves | 2.94 | 18.63 | 27.38 |
| Borrowings | 15.13 | 22.16 | 28.94 |
| Other Liabilities | 13.18 | 11.6 | 17.59 |
| Total Liabilities | 34.53 | 56.42 | 77.94 |
| Fixed Assets | 10.25 | 13.1 | 16.06 |
| CWIP | 0.03 | 4.62 | 12.85 |
| Investments | 0.03 | 0.03 | 0.03 |
| Other Assets | 24.22 | 38.67 | 49 |
| Total Assets | 34.53 | 56.42 | 77.94 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | 1.02 | 3.39 | 2.78 |
| Investing | -3.9 | -9.55 | -9.04 |
| Financing | 2.93 | 10.21 | 3.07 |
| Net Cash Flow | 0.05 | 4.05 | -3.19 |
| Free Cash Flow | -2.81 | -5.88 | -6.43 |
| CFO/OP | 29 | 36 | 35 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 124 | 140 | 146 |
| Inventory Days | 290 | 176 | 218 |
| Days Payable | 130 | 98.06 | 120 |
| Cash Conversion Cycle | 284 | 218 | 244 |
| Working Capital Days | 28.64 | 70.29 | 74.03 |
| ROCE % | — | 34.18% | 26.64% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Avience Biomedicals insights
47 extracted metrics + investor summaries across FY24–FY26.
Documents
1
Copy of Newspaper Publication
9 Sep - Newspaper ads confirm annual report dispatch; 7th AGM on September 30, 2026 via VC/OAVM. 9 Sep - Newspaper ads confirm annual report dispatch; 7th AGM on September 30, 2026 via VC/OAVM.
2
Copy of Newspaper Publication
8 Sep - Newspaper publication shared for Avience Biomedicals’ 7th AGM on September 30, 2026 at 11:30 A.M. 8 Sep - Newspaper publication shared for Avience Biomedicals’ 7th AGM on September 30, 2026 at 11:30 A.M.
3
Updates
8 Sep - Notice of 7th AGM on 30 Sep 2026; seeks auditor changes and borrowing powers up to Rs100 crore. 8 Sep - Notice of 7th AGM on 30 Sep 2026; seeks auditor changes and borrowing powers up to Rs100 crore.
4
Shareholders meeting
8 Sep - 7th AGM on 30 Sep 2026; adopts FY26 accounts, auditor appointments, and borrowing powers up to Rs100 crore. 8 Sep - 7th AGM on 30 Sep 2026; adopts FY26 accounts, auditor appointments, and borrowing powers up to Rs100 crore.
5
Updates
8 Sep - AGM notice and annual report web links shared with shareholders. 8 Sep - AGM notice and annual report web links shared with shareholders.
Frequently Asked Questions about Avience Biomedicals
What does Avience Biomedicals Ltd do?
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]
Where is Avience Biomedicals Ltd (AVIENCE) listed?
Avience Biomedicals Ltd trades as AVIENCE on the NSE.
Which sector does Avience Biomedicals Ltd belong to?
Avience Biomedicals Ltd is classified under the Healthcare sector, in the Healthcare Equipment & Supplies industry.
What is the market capitalisation of Avience Biomedicals Ltd?
Avience Biomedicals Ltd has a market capitalisation of ₹182.93 Cr, which places it in the Small Cap band.
What is the PE ratio of Avience Biomedicals Ltd?
Avience Biomedicals Ltd trades at a PE ratio of 21.70, against a book value of ₹164.88 per share.
What is the 52-week high and low of Avience Biomedicals Ltd?
Over the last 52 weeks Avience Biomedicals Ltd has traded between ₹208 and ₹414.95.
What is the Return on Equity (ROE) of Avience Biomedicals Ltd?
Avience Biomedicals Ltd reported a return on equity of 31.33%. Its debt-to-equity ratio is 0.92.
Company Information
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AVIENCE.md for Avience Biomedicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.